Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 2/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.50 |
| ▸ | ACLY | P53396 | 1/20 | 0.49 |
| ▸ | SCN9A | Q15858 | 13/20 | 0.47 |
| ▸ | SCN5A | Q14524 | 6/20 | 0.47 |
| ▸ | SCN2B | O60939 | 5/20 | 0.47 |
| ▸ | SCN1B | Q07699 | 5/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.47 |
| ▸ | SCN1A | P35498 | 3/20 | 0.45 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.45 |
| ▸ | P4HTM | Q9NXG6 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22503216 | 0.81 | HDAC1 (0.47) | HDAC1HDAC6SCN9ASCN5APTPN1 | |
| SCHEMBL18013245 | 0.81 | ACLY (0.49) | HDAC1HDAC6ACLYSCN9ASCN5A | |
| SCHEMBL714409 | 0.80 | HDAC6 (0.43) | HDAC1HDAC6ACLYSCN9A | |
| SCHEMBL2296845 | 0.80 | HDAC6 (0.51) | HDAC1HDAC6 | |
| SCHEMBL13236623 | 0.79 | P4HTM (0.49) | HDAC1HDAC6SCN9ASCN5ASCN2B | |
| SCHEMBL31213533 | 0.78 | HDAC1 (0.53) | HDAC1HDAC6 | |
| SCHEMBL5924147 | 0.78 | HDAC1 (0.53) | HDAC1HDAC6 | |
| SCHEMBL22097524 | 0.77 | SCN9A (0.47) | HDAC1HDAC6SCN9ASCN5ASCN2B | |
| SCHEMBL18013247 | 0.77 | ACLY (0.46) | ACLYSCN9ASCN5ASCN2BSCN1B | |
| SCHEMBL5596417 | 0.77 | HDAC1 (0.49) | HDAC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200148634-A1 | ACLY INHIBITORS AND USES THEREOF | Nimbus Artemis, Inc. | 2020-05-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200148634-A1 | ACLY INHIBITORS AND USES THEREOF | ACLY, ATP5ME, ATP5MG | HDAC1 1861/4885HDAC6 920/4885ACLY 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.